A Randomized, Placebo Controlled Clinical Trial of SOM230 (Pasireotide LAR) In Severe Polycystic Liver Disease.
Latest Information Update: 29 Dec 2021
At a glance
- Drugs Pasireotide (Primary)
- Indications Polycystic liver disease
- Focus Therapeutic Use
- Acronyms SOM230
- 01 May 2019 Status changed from active, no longer recruiting to completed.
- 18 Oct 2017 Planned End Date changed from 1 Dec 2018 to 1 Jan 2019.
- 18 Oct 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jul 2018.